Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-11

Clinical Trial Update: Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum [Phase 2]

View source ↗

Summary

Phase 2 trial of APD334 in pyoderma gangrenosum was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • APD334

Snippet

Sponsor: Arena Pharmaceuticals | Conditions: Pyoderma Gangrenosum | Phase 2 | Status: TERMINATED | Results posted: 2021-06-11